Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PrecipioPRPO -1.57%51 3-Year Book Growth Rate is -17.00% as of Jun. 2026. GuruFocus rates PRPO with a GF Score™ of 51/100 and a GF Value™ of $10.63 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Precipio ranks worse than 74.23% on this metric.
During the past 12 months, Precipio's average Book Value per Share Growth Rate was 1.80% per year.
During the past 3 years, the average Book Value per Share Growth Rate was -17.00% per year.
During the past 5 years, the average Book Value per Share Growth Rate was -17.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Precipio was -14.20% per year. The lowest was -65.20% per year. And the median was -25.90% per year.
Precipio (NAS:PRPO) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Precipio 3-Year Book Growth Rate Related Terms
PRPO vs IDXGD, MDXH, BIOQ: 3-Year Book Growth Rate Comparison
For the Diagnostics & Research subindustry, Precipio's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Precipio 3-Year Book Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Precipio's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Precipio's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of -17.00% mean?
Precipio (PRPO) has a 3-Year Book Growth Rate of -17.00% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Precipio and its competitors. According to the industry distribution chart, Precipio ranks #144 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 74.2%.
Is Precipio's 3-Year Book Growth Rate too high?
Precipio's current 3-Year Book Growth Rate is -17.00%. Based on the distribution chart, Precipio ranks #144 out of 194 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Precipio has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Precipio's 3-Year Book Growth Rate compare to IDXGD and MDXH?
According to the Medical Diagnostics & Research industry distribution chart, Precipio ranks #144 out of 194 companies for 3-Year Book Growth Rate. This places Precipio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Medical Diagnostics & Research company?
A good 3-Year Book Growth Rate depends on the Medical Diagnostics & Research industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Precipio and its competitors. Precipio's current 3-Year Book Growth Rate is -17.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precipio stock overvalued right now?
Based on GuruFocus' analysis, Precipio (PRPO) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.63, compared to a current price of $28.60 — trading 169% above its estimated fair value. The current 3-Year Book Growth Rate is -17.00%. Precipio's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Precipio (PRPO), the current 3-Year Book Growth Rate is -17.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Precipio (PRPO) Overvalued in 2026?
Based on GuruFocus' analysis, Precipio stock appears to be overvalued.
The current stock price of $28.60 is trading 169% above its estimated GF Value™ of $10.63.
GuruFocus considers Precipio to be Significantly Overvalued.
Key valuation signals for PRPO:
3-Year Book Growth Rate: -17.00%
GF Value™: $10.63 vs. price of $28.60 (169% above fair value)
No single metric tells the full story. See the PRPO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.
51GF Score
Get the complete analysis for PRPO
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRPO has been successfully added to your 
